Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company

Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange

Fineline Cube Dec 28, 2024

On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...

Company

MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award

Fineline Cube Dec 28, 2024

The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...

Company Drug

Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer

Fineline Cube Dec 27, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...

Company

AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions

Fineline Cube Dec 27, 2024

UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...

Company Drug Hospital Medical Device Policy / Regulatory

Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme

Fineline Cube Dec 27, 2024

The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...

Company Deals Drug

Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program

Fineline Cube Dec 27, 2024

US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...

Company Deals

Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach

Fineline Cube Dec 27, 2024

China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...

Company Drug

Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS

Fineline Cube Dec 27, 2024

Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...

Company Drug

Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment

Fineline Cube Dec 27, 2024

China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...

Company Deals

Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China

Fineline Cube Dec 27, 2024

Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...

Company Drug

Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC

Fineline Cube Dec 27, 2024

China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...

Company Deals

Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition

Fineline Cube Dec 27, 2024

China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...

Company Deals Drug

Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery

Fineline Cube Dec 27, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...

Company Deals

AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy

Fineline Cube Dec 27, 2024

Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...

Company Drug

Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval

Fineline Cube Dec 27, 2024

China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...

Company Deals

Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories

Fineline Cube Dec 27, 2024

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...

Company Drug

Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study

Fineline Cube Dec 27, 2024

China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...

Company Drug

China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval

Fineline Cube Dec 27, 2024

On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...

Company Drug

Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)

Fineline Cube Dec 26, 2024

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...

Company Drug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Fineline Cube Dec 26, 2024

China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...

Posts pagination

1 … 181 182 183 … 609

Recent updates

  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
  • Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
  • ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
  • Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
  • U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.